BioNexus attended a working visit to Tongshu Gene facilities in Shanghai and Changzhou to advance the VitaGuard MRD platform rollout in Southeast Asia.
Sessions mapped implementation needs, with site visits to Chinese hospitals using VitaGuard commercially supporting BioNexus’s 2026 initial deployment target.
BGLC•
